Per earlier note we are long on $NUVA from $40.30. Take partial profits right here at $42.30 and tighten the stop band.
… Please click here or the title below to read more.The FDA Peripheral and Central Nervous System Drugs Advisory Committee meets today to review ACOR’s Fampridine-SR for improvement of walking in patients with multiple sclerosis .
We have been negative on ACOR from the very beginning of Fampridine saga because even if the drug works as ACOR promotes, it is not a very good drug. Moreover, the number of participants in ACOR studies have been relatively small compared to what we think it should be to fully evaluate the risk of seizures. We also think the studies are flawed in how they measure the walking ability. Measurement of anything in MS patients is subjective at best in the first place.… Please click here or the title below to read more.